Belgium - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, UCB SA/NV ('UCB' or the 'Company) (Euronext Brussels: UCB) hereby discloses certain information in relation to its Share Repurchase Program 2024.

Under this program, UCB has requested a financial intermediary to repurchase up to 1,300,000 UCB shares on its behalf under the terms of a discretionary mandate agreement with initial validity until 30 June 2024, effective as from 02 April 2024, to cover current and future obligations under UCB's Long Term Incentive Plans for its personnel.

Contact:

Antje Witte

Tel: +32 2 559 94 14

Email: Antje.Witte@ucb.com

Laurent Schots

Tel: +32 2 559 92 64

Email: laurent.schots@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of EUR5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB).

(C) 2024 Electronic News Publishing, source ENP Newswire